Invivyd, Inc. Common Stock
IVVDInvivyd, Inc. (IVVD) is a biotechnology company focused on developing innovative therapeutics and vaccines for infectious diseases, with an emphasis on viral pathogens. The company utilizes antibody-based and other advanced technologies to create treatments aimed at preventing and combating infectious illnesses.
Company News
Invivyd, Inc. announced a partnership with Olympic skier Lindsey Vonn to launch a national multimedia educational campaign in spring 2026 focused on teaching Americans about antibodies and disease prevention. Vonn will serve as the public-facing spokesperson for the initiative, leveraging her credibility and comeback story to advance public under...
Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% year-over-year growth and 31% quarter-over-quarter growth. The company announced a strong balance sheet with $226.7 million in cash after raising over $200 million in 2H 2025. Key developments include initiation of the DECLARATION Phase 3 pivotal trial for CO...
Invivyd is conducting a public offering of 44 million common stock shares and 6 million pre-funded warrants at $2.50 per share, expecting to raise approximately $125 million to fund commercial preparedness, research and development, and corporate purposes.
Invivyd completed a public offering of 89,234,480 shares and pre-funded warrants, raising approximately $57.5 million to fund clinical trials, research and development, and corporate purposes.
Invivyd is conducting a public offering of 74,811,404 common stock shares and pre-funded warrants, expecting to raise approximately $50 million to fund clinical trials, research and development, and corporate purposes.
